2.04

7.27% -0.16

After Hours: 2.08 0.04 +1.96%

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $2.04, with a volume of 3.01M. It is down -7.27% in the last 24 hours and down -20.00% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$2.20

Open:

$2.19

24h Volume:

3.01M

Relative Volume:

0.77

Market Cap:

$196.38M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.2289

EPS:

-1.66

Net Cash Flow:

$-54.24M

1W Performance:

-5.12%

1M Performance:

-20.00%

6M Performance:

+25.15%

1Y Performance:

-23.31%

1-Day Range:

$2.00

$2.22

1-Week Range:

$2.00

$2.275

52-Week Range:

$0.9857

$3.67

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

151

Twitter

@CabalettaBio

Next Earnings Date

2025-03-31

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	2.04	211.78M	0	-67.68M	-54.24M	-1.66
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Resumed	Jefferies	Buy
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

Jan 05, 2026

Is Cabaletta Bio Inc a good long term investmentPrice Volatility Patterns & Free High Profit Capital Plays - earlytimes.in

Jan 05, 2026

Jan 04, 2026

Cabaletta Bio slides on proposed securities offering - MSN

Jan 04, 2026

Jan 03, 2026

Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN

Jan 03, 2026

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 03, 2026

Dec 31, 2025

Smart Money: Is Cabaletta Bio Inc stock a top momentum playMarket Trend Summary & Technical Buy Zone Confirmations - moha.gov.vn

Dec 31, 2025

Dec 30, 2025